Is ADMA Biologics, Inc. overvalued or undervalued?

As of 18 June 2025, the valuation grade for ADMA Biologics, Inc. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially in light of its strong performance metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 30.78, and an impressive ROE of 55.71%.
When compared to peers, ADMA Biologics has a lower P/E ratio than Protagonist Therapeutics, which stands at 60.90, highlighting its relative undervaluation. Additionally, the PEG ratio of 0.03 suggests that the company is priced attractively relative to its growth potential. Despite a recent decline in stock price over the past week, ADMA Biologics has outperformed the S&P 500 over the past year with a return of 62.45% compared to the index's 10.26%, reinforcing its strong valuation narrative.